GLOBAL-BLUE
21.4.2021 12:33:09 CEST | Business Wire | Press release
Global Blue, today, announced the launch of Global Blue Ventures, a new entity created to identify, invest in and/or partner with third parties that offer market-leading retail technology solutions.
Global Blue Ventures was initiated in 2019, and officially launched in April 2021, to advance Global Blue’s ambition to be a strategic omnichannel technology and payments partner empowering merchants to improve their performance.
Extending Global Blue’s value proposal with innovative omnichannel solutions
Global Blue Ventures concentrates on innovative and promising new businesses, with best-in-class companies selected to support brands on their omnichannel path.
The Ventures program will focus on add-on technologies that can easily integrate with retailers’ core systems, allowing them to:
- Optimise and digitalise their processes across the entire omnichannel customer journey: online, in store and at home
- Capture customers’ identity and engage with them on a personalised one-to-one basis
- Collect and cross-reference data to provide advisory services and actionable insights
It will focus its efforts on three key verticals and market needs:
- eCommerce: how to boost conversion rates and improve return efficiency
- Store digitalisation: how to digitalise in-store processes and experiences
- Clienteling 2.0: how to engage digitally one-to-one with consumers
RetailTech market experts James Strabo, previously a founding member and Managing Director at Blackhawk Network and Managing Director at Westfield (OneMarket), and Andrew Carroll, Founder of Yocuda and formerly Director of Corporate Development at Westfield (OneMarket) will lead Global Blue Ventures. Their mission will be to pinpoint latest retail market trends, identify the best-in-class technology players for each vertical, test and collect retailers’ feedback and, where appropriate, drive investments in the retail technology partners that can further accelerate Global Blue’s omnichannel market expansion.
Advancing with investment in promising new verticals
Since its inception, Global Blue Ventures has already enabled Global Blue to join forces with several leading players including:
- Yocuda: in October 2020, Global Blue acquired a minority stake in Yocuda, a leading digital receipt provider. Yocuda allows retailers to send content-rich, personalised digital receipts to consumers, whilst capturing data that allows for customer insight, management and engagement. Its technology can also be linked to a brand loyalty programmes. Yocuda is partnered with leading companies such as Marks & Spencer and Argos.
- ZigZag Global: in March 2021, Global Blue announced the acquisition of ZigZag Global, a leading Software-as-a-Service (SaaS) technology provider. ZigZag replaces the traditional paper-based “label in the box” returns solution with an online portal that enhances the experience for consumers and streamlines the process for retailers across the world. ZigZag is partnered with leading retailers such as Selfridges and Superdry.
Jacques Stern, CEO of Global Blue: “As a technology and payment partner for retailers, we are looking at extending our solutions on the full omnichannel journey, for both domestic and international shoppers. The network of RetailTech companies that we have started to create through Global Blue Ventures will enable us to co-create integrated solutions that achieve this goal and ensure we continue to meet our clients’ evolving needs.”
James Strabo and Andrew Carroll, Founding Partners of Global Blue Ventures: “ We are very pleased to be joining Global Blue and look forward to bringing our vision and expertise to help propel the business further into the RetailTech space. We are confident that the network of RetailTech partners we will build will give Global Blue clients access to the best-in-class solutions and will enable them to stay at the forefront of the latest omnichannel trends.”
ABOUT GLOBAL BLUE
Global Blue is a long-standing and trusted partner for retailers across the world. Its omnichannel technology and payments solutions empower its clients to improve their performance in the following areas:
- Tax Free Shopping: After pioneering the concept of Tax-Free Shopping more than 40 years ago, Global Blue’s integrated technology solutions at 300,000 points of sale offer 13 million international shoppers a seamless and personalised experience when claiming back the VAT on goods purchased abroad.
- Added Value Payment Solutions: Global Blue partners with more than 50 acquirers and Payment Service Providers across the world to provide retailers and hoteliers with a best-in-class FX solution that serves 16 million travellers and online shoppers at more than 130,000 points of interaction.
- Ecommerce returns: Global Blue offers, through its ZigZag Global brand, an enhanced, fully digital returns experience to more than 12 million domestic shoppers by connecting retailers to a network of more than 450 carrier services and 220 warehouses in 130 countries.
A unique understanding of shoppers and their shopping history enables Global Blue to provide Advisory Business Intelligence services, helping retailers to identify revenue and costs opportunities, while its Consumer Engagement solutions help retailers to capture growth opportunities.
In the financial year ending 31 March 2020, Global Blue processed 35 million Tax Free Shopping transactions with a total value of €18.5 billion sales in store, and 31 million Added-Value Payment Solutions transactions with a total value of €4.4 billion sales in store. Global Blue has almost 1,500 employees and is present in more than 50 countries.
Global Blue is listed on the New York Stock Exchange under the ticker GB.
For more information : globalblue.com/corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005512/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
